HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

Food and Drug Administration (FDA) Commissioner Marty Makary committed to reviewing the abortion drug mifepristone in a letter sent to Sen. Josh Hawley (R-Mo.). “As with all drugs, FDA continues ...

Four Democrat-led states ask FDA to remove abortion pill restrictions. The attorneys general of New York, California, Massachusetts and New Jersey asked the FDA to lift some requirements on ...

Attorneys general from four states are asking the U.S. Food and Drug Administration (FDA) to lift restrictions on mifepristone, a pill used in medication abortions.

Days after FDA Commissioner Marty Makary said that the agency planned to review the safety of abortion pill mifepristone, attorneys general from four pro-choice states have fired back, filing (PDF ...

FDA regulations on mifepristone, the first medication involved in the two-part medication abortion protocol, have been a flashpoint in the abortion debate since the 2022 Dobbs v.Jackson Women’s ...

Debate over the abortion pill mifepristone resurfaces after Makary is confirmed to head the FDA. Mar 26, 2025. Case involving access to abortion pill moves to appeals court. May 17, 2023.

Health and Human Services Secretary Robert Kennedy Jr. asked the FDA last month to review mifepristone. FDA Commissioner Marty Makary said he would do so, in correspondence released on June 2 ...

Presented by Alliance for Pharmacy Compounding — The Food and Drug Administration commissioner has committed to reviewing the abortion drug mifepristone after previously stating he had no plans ...

FRIDAY, June 6, 2025 (HealthDay News) — Attorneys general from four states are asking the U.S. Food and Drug Administration (FDA) to lift restrictions on mifepristone, a pill used in medication ...

FDA Commissioner Marty Makary wrote a letter to pro-life Senator Josh Hawley (R., Mo.) Monday informing him of the agency’s plan to conduct a review of mifepristone.

The study was based on insurance claims for 865,727 mifepristone abortions between 2017 and 2023. "I'm calling on the FDA to reinstate safety regulations on the chemical abortion drug immediately.